Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study-Reference-Cited by-同舟云学术

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study

Published:2011-10 Issue:1 Volume:123 Page:19-26
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Behbakht Kian,Sill Michael W.,Darcy Kathleen M.,Rubin Stephen C.,Mannel Robert S.,Waggoner Steven,Schilder Russell J.,Cai Kathy Q.,Godwin Andrew K.,Alpaugh R. Katherine

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference79 articles.

1. Cancer statistics, 2008;Jemal;CA Cancer J Clin,2008

2. Epithelial ovarian cancer: a review of current management;Guppy;Clin Oncol (R Coll Radiol),2005

3. Systemic therapy for ovarian cancer: current status and new treatments;Ozols;Semin Oncol,2006

4. Ras, PI(3)K and mTOR signalling controls tumour cell growth;Shaw;Nature,2006

5. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells;Sun;Am J Pathol,2001

Cited by 172 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FANCD2 expression affects platinum response and further characteristics of high grade serous ovarian cancer in cells with different genetic backgrounds;Experimental and Molecular Pathology;2024-08

2. Circulating Tumor Cells: How Far Have We Come with Mining These Seeds of Metastasis?;Cancers;2024-02-17

3. Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers;International Journal of Molecular Sciences;2024-02-06

4. The role of liquid biopsy in epithelial ovarian cancer: State of the art;Critical Reviews in Oncology/Hematology;2024-02

5. Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4;Therapeutic Advances in Medical Oncology;2024-01